Scottish Medicines Consortium approves herceptin to treat patients with gastric cancer
The Scottish Medicines Consortium (SMC) has granted approval for herceptin (trastuzumab) for routine use in the NHS to treat patients in Scotland with an advanced and incurable form of gastric cancer (stomach and gastro-oesophageal).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Herceptin | Pharmaceuticals | Scotland Health